BioAge Labs FY2024 net loss $71.1M; advances NLRP3 inhibitor BGE-102; discontinues azelaprag

BioAge Labs, Inc.

Net loss of $71.1M ($6.63/share) for FY2024; cash $354.3M expected to fund operations through 2029.
Discontinued azelaprag Phase 2 STRIDES trial due to unexpected liver transaminitis; continuing next-generation APJ agonists.
Nominated BGE-102, an oral brain-penetrant NLRP3 inhibitor; Phase 1 SAD data expected 2H25, MAD data 1H26.
New collaborations: Novartis (up to $20M upfront, $530M milestones) and Lilly (antibody discovery for metabolic aging targets).
R&D expenses $59.0M (up 74% YoY); G&A $19.2M (up 32% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.